In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...

the Company’s long-acting glucagon-like peptide 1 (GLP-1) receptor antagonist in development for the treatment of ...